The Food and Drug Administration Friday reissued its emergency use authorization for the LabCorp COVID-19 RT-PCR Test to include authorized use for asymptomatic individuals and for pooled sample testing with up to five individual specimens. FDA previously authorized emergency use of the test for patients with suspected COVID-19 and individual specimens.

“FDA’s authorization of the first diagnostic test to be used for anyone, regardless of whether they are showing symptoms of COVID-19 or have other exposure risk factors, is a step toward the type of broad screening that may help enable the reopening of schools and workplaces,” said FDA Commissioner Stephen Hahn, M.D. “By authorizing another test for use with pooled samples, we also further help increase the possibility that patients may be able to receive results sooner, while also conserving vital testing supplies, which are under increased demand during the pandemic.”

Related News Articles

Headline
Health and Human Services Secretary Xavier Becerra this week amended the February 2020 COVID-19 emergency use authorization declaration so that the Food…
Headline
Just in time for March Madness, AHA is offering for hospitals and health systems a social media toolkit that uses the wildly popular NCAA basketball tournament…
Headline
The Food and Drug Administration yesterday amended its emergency use authorization for Pfizer’s updated COVID-19 vaccine to allow children aged 6 months…
Headline
The Food and Drug Administration will end 22 COVID-19-related policies when the public health emergency ends May 11 and allow 22 to continue for 180 days,…
Headline
Qualified family members of health care workers whose lives were lost to COVID-19 may apply through April 20 at 3 p.m. CT for a Brave of Heart Scholarship. The…
Headline
Dwayne Gordon, M.D., and Richard Pratley, M.D., share lessons learned from AdventHealth’s multidisciplinary approach to caring for patients who experience…